CA Patent

CA3112584A1 — Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses

Assigned to US Department of Health and Human Services · Expires 2020-03-26 · 6y expired

What this patent protects

An embodiment of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the C…

USPTO Abstract

An embodiment of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA3112584A1
Jurisdiction
CA
Classification
—
Expires
2020-03-26
Drug substance claim
No
Drug product claim
No
Assignee
US Department of Health and Human Services
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.